Wollin; Stefan-Lutz

Patent Applications and Registrations

Patent applications and USPTO patent grants for Wollin; Stefan-Lutz.The latest application filed is for "combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases".

Company Profile

0.3.11

Wollin; Stefan-Lutz - Bad Waldsee DE
Wollin; Stefan-Lutz - Meersburg DE
Wollin; Stefan-Lutz - Bad Waldse DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases Grant 9,713,614 - Wollin , et al. July 25, 2	2017-07-25
Combination Of Hmg-coa Reductase Inhibitors With Phosphodiesterase 4 Inhibitors For The Treatment Of Inflammatory Pulmonary Diseases App 20150272949 - WOLLIN; Stefan-Lutz ; et al.	2015-10-01
Composition comprising a pulmonary surfactant and a TNF-derived peptide Grant 8,236,750 - Schaefer , et al. August 7, 2	2012-08-07
Combination of HMG-COA Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Disease App 20100069392 - Wollin; Stefan-Lutz	2010-03-18
Composition Comprising a Pulmonary Surfactant and a Tnf-Derived Peptide App 20070299003 - Schaefer; Klaus P. ; et al.	2007-12-27
Use of Roflumilast for the Prophylaxis or Treatment of Emphysema App 20070254928 - Wollin; Stefan-Lutz ; et al.	2007-11-01
Composition comprising a pulmonary surfactant and a PDE5 inhibitor for the treatment of lung diseases Grant 7,238,664 - Wollin July 3, 2	2007-07-03
Composition comprising a pulmonary surfactant and a pde2 inhibitor App 20060229242 - Wollin; Stefan-Lutz	2006-10-12
Synergistic combination comprising roflumilast and (r,r) - formoterol App 20060199865 - Beume; Rolf ; et al.	2006-09-07
Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases App 20060189642 - Bundschuh; Daniela ; et al.	2006-08-24
Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases App 20060148693 - Wollin; Stefan-Lutz	2006-07-06
Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases App 20060147382 - Bundschuh; Daniela ; et al.	2006-07-06
Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist App 20050112069 - Beume, Rolf ; et al.	2005-05-26
Combination App 20050014762 - Beume, Rolf ; et al.	2005-01-20

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.